• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Clarivate’s Expanded Agentic AI Across Cortellis Reshape the Bull Case For Clarivate (CLVT)?

    Simply Wall St·08/13/2026 04:58:11
    Listen to the news
    • In August 2026, Clarivate Plc expanded agentic AI capabilities across its Cortellis life sciences portfolio, embedding AI into drug discovery, safety assessment and portfolio decision workflows to reduce manual effort and support faster, evidence-based decisions.
    • By integrating multi-agent AI directly into Cortellis tools like Drug Discovery Intelligence, OFF-X and Competitive Intelligence, Clarivate is turning previously time-intensive R&D and market analysis tasks into higher-value, insight-driven workflows for researchers, safety teams and business development professionals.
    • We’ll now examine how Clarivate’s expanded agentic AI across Cortellis could reshape its investment narrative around workflow integration and efficiency.

    Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Clarivate Investment Narrative Recap

    To own Clarivate, you need to believe its data and workflow tools can remain essential even as AI and free information expand. The Cortellis agentic AI rollout directly supports the near term catalyst of deeper workflow integration, but it does not remove key risks such as competition from open access data, pressure on pricing, and the company’s continuing net losses and leverage.

    The Cortellis AI expansion sits alongside Clarivate’s broader AI push, including the March 2026 integration of Cortellis Regulatory Intelligence into Claude’s AI environment. Together, these moves point to a company trying to embed AI into customers’ daily work and reinforce subscription stickiness at a time when analysts are concerned about revenue pressure and the impact of prior divestitures on reported growth.

    Yet beneath the AI story, investors should still be aware of Clarivate’s high debt load and...

    Read the full narrative on Clarivate (it's free!)

    Clarivate's narrative projects $1.9 billion revenue and $142.7 million earnings by 2029. This assumes revenues will decline by 7.4% per year and requires an earnings increase of about $280 million from -$137.4 million today.

    Uncover how Clarivate's forecasts yield a $2.50 fair value, a 34% upside to its current price.

    Exploring Other Perspectives

    CLVT 1-Year Stock Price Chart
    CLVT 1-Year Stock Price Chart

    Some of the lowest ranked analysts see a tougher road than the consensus, assuming revenue falls toward about US$2.0 billion and only US$18.6 million of earnings by 2029, so if you are weighing Cortellis’ new AI against these views, remember that opinions differ widely and this update could shift how both the bullish and bearish camps think about Clarivate’s long term potential.

    Explore 4 other fair value estimates on Clarivate - why the stock might be worth just $2.00!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready To Venture Into Other Investment Styles?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.